<?xml version='1.0' encoding='utf-8'?>
<document id="24843581"><sentence text="Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study."><entity charOffset="37-48" text="repaglinide" /><entity charOffset="63-74" text="clopidogrel" /></sentence><sentence text="Repaglinide is widely prescribed to reduce postprandial hyperglycemia and elevated glycated hemoglobin (HbA1c) levels associated with type 2 diabetes, and clopidogrel is a thienopyridine antiplatelet agent and widely used in cardiovascular and cerebrovascular diseases"><entity charOffset="0-11" text="Repaglinide" /><entity charOffset="155-166" text="clopidogrel" /><entity charOffset="172-186" text="thienopyridine" /></sentence><sentence text=" It has been suggested that the concomitant use of repaglinide with clopidogrel may inhibit repaglinide metabolism, because repaglinide is a substrate of cytochrome P450 2C8 (CYP2C8) and the main metabolite of clopidogrel acyl-β-D-glucuronide inhibits CYP2C8 activity"><entity charOffset="51-62" text="repaglinide" /><entity charOffset="68-79" text="clopidogrel" /><entity charOffset="92-103" text="repaglinide" /><entity charOffset="124-135" text="repaglinide" /><entity charOffset="210-242" text="clopidogrel acyl-β-D-glucuronide" /></sentence><sentence text=" In this study, we retrospectively investigated the effect of clopidogrel with repaglinide on plasma glucose and the risk of hypoglycemia associated with the combination of both drugs"><entity charOffset="62-73" text="clopidogrel" /><entity charOffset="79-90" text="repaglinide" /><entity charOffset="101-108" text="glucose" /></sentence><sentence text="" /><sentence text="Patients were taking clopidogrel (75 mg/day) and started taking glinide (1"><entity charOffset="21-32" text="clopidogrel" /><entity charOffset="64-71" text="glinide" /></sentence><sentence text="5 mg/day repaglinide or 30 mg/day mitiglinide) for the first time from April 2012 to March 2017"><entity charOffset="9-20" text="repaglinide" /><entity charOffset="34-45" text="mitiglinide" /></sentence><sentence text=" We targeted subjects who were hospitalized at the start of glinide and whose preprandial plasma glucose was measured by a nurse"><entity charOffset="97-104" text="glucose" /></sentence><sentence text=" The glucose levels were collected for up to 5 days before and after the glinide start date"><entity charOffset="5-12" text="glucose" /></sentence><sentence text="" /><sentence text="Average fasting plasma glucose levels (before breakfast) in the repaglinide and clopidogrel group before and after starting repaglinide were 180"><entity charOffset="23-30" text="glucose" /><entity charOffset="64-75" text="repaglinide" /><entity charOffset="80-91" text="clopidogrel" /><entity charOffset="124-135" text="repaglinide" /></sentence><sentence text="1±35" /><sentence text="5 and 136" /><sentence text="5 ± 44" /><sentence text="1 mg/dL, with a mean decrease of 43" /><sentence text="6 ± 33" /><sentence text="6 mg/dL" /><sentence text=" In contrast, there was only a moderate decrease of 11" /><sentence text="6 ± 30" /><sentence text="0 mg/dL in the mitiglinide and clopidogrel group"><entity charOffset="15-26" text="mitiglinide" /><entity charOffset="31-42" text="clopidogrel" /></sentence><sentence text=" Minimum plasma glucose levels in the repaglinide and clopidogrel group before and after starting repaglinide were 145"><entity charOffset="16-23" text="glucose" /><entity charOffset="38-49" text="repaglinide" /><entity charOffset="54-65" text="clopidogrel" /><entity charOffset="98-109" text="repaglinide" /></sentence><sentence text="2 ± 42" /><sentence text="9 and 93" /><sentence text="3 ± 36" /><sentence text="3 mg/dL, respectively" /><sentence text=" Decrease in minimum levels after starting glinide in the repaglinide and clopidogrel group (51"><entity charOffset="43-50" text="glinide" /><entity charOffset="58-69" text="repaglinide" /><entity charOffset="74-85" text="clopidogrel" /></sentence><sentence text="9 ± 47" /><sentence text="5 mg/dL) was more significant than those in the mitiglinide and clopidogrel group (only 2"><entity charOffset="48-59" text="mitiglinide" /><entity charOffset="64-75" text="clopidogrel" /></sentence><sentence text="1 ± 29" /><sentence text="1 mg/dL), and the repaglinide group (without clopidogrel, 15"><entity charOffset="18-29" text="repaglinide" /><entity charOffset="45-56" text="clopidogrel" /></sentence><sentence text="5 ± 20" /><sentence text="0 mg/dL)" /><sentence text=" Hypoglycemia was observed in 6 of 15 patients in the repaglinide and clopidogrel group, but only 1 of 15 patients in the mitiglinide and clopidogrel group, and no patients in the repaglinide group"><entity charOffset="54-65" text="repaglinide" /><entity charOffset="70-81" text="clopidogrel" /><entity charOffset="122-133" text="mitiglinide" /><entity charOffset="138-149" text="clopidogrel" /><entity charOffset="180-191" text="repaglinide" /></sentence><sentence text="" /><sentence text="These findings indicate that minimum plasma glucose levels were significantly decreased in patients taking repaglinide and clopidogrel"><entity charOffset="44-51" text="glucose" /><entity charOffset="107-118" text="repaglinide" /><entity charOffset="123-134" text="clopidogrel" /></sentence><sentence text=" Considering the risk of hypoglycemia associated with taking repaglinide and clopidogrel, when a glinide is required in patients taking clopidogrel, mitiglinide may be a better choice"><entity charOffset="61-72" text="repaglinide" /><entity charOffset="77-88" text="clopidogrel" /><entity charOffset="97-104" text="glinide" /><entity charOffset="136-147" text="clopidogrel" /><entity charOffset="149-160" text="mitiglinide" /></sentence><sentence text="" /></document>